Clinical Trials
63 trialsNCT01453088 2026-03-24
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Phase 2 Terminated
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT04570631 2025-05-16
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT04892446 2025-05-02
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Gilead Sciences
Phase 2 Terminated
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT04956302 2024-06-06
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04912427 2024-02-09
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Washington University School of Medicine
Phase 1 Terminated
NCT02188368 2023-11-03
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT01177683 2023-10-06
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT03481556 2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2 Terminated
NCT00464178 2022-07-20
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT00256776 2021-10-18
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT03117361 2020-12-02
Trial of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
PharmaMar
Phase 2 Terminated
NCT00985907 2020-06-17
DMV
University of California, San Francisco
Phase 1/2 Terminated
NCT02928029 2020-02-26
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Bayer
Phase 1/2 Terminated
NCT01438177 2020-02-24
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
Phase 2 Terminated
NCT02773550 2020-01-18
Velcadito
Basque Health Service
Phase 4 Terminated
NCT00765102 2019-11-25
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Celgene
Phase 2 Terminated
NCT00920556 2019-02-27
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
GlaxoSmithKline
Phase 2 Terminated
NCT01470131 2018-12-19
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
AB Science
Phase 3 Terminated
NCT01672736 2018-09-13
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
University Health Network, Toronto
Phase 1/2 Terminated
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT00124579 2018-08-09
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Terminated
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT01002248 2018-02-09
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
AEterna Zentaris
Phase 3 Terminated
NCT01315873 2018-02-07
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Phase 2 Terminated
NCT00744354 2018-01-18
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00574080 2017-11-20
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
University of Arkansas
Phase 3 Terminated
NCT00657553 2017-11-20
2007-77
University of Arkansas
Phase 3 Terminated
NCT00849251 2017-09-08
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
University of Washington
Phase 1/2 Terminated
NCT01720043 2017-09-05
Hemostatic Effects of VELCADEĀ®* Treatment in Multiple Myeloma Patients
University of Utah
Phase 2 Terminated
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT01729338 2017-05-31
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Duke University
Phase 2 Terminated
NCT01534143 2017-04-05
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00560352 2017-03-13
Safety Study of Dasatinib With Bortezomib (VelcadeĀ®) and Dexamethasone for Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Terminated
NCT01954784 2017-02-17
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT02254551 2017-02-16
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01695330 2017-01-16
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
Oncotherapeutics
Phase 2 Terminated
NCT00984828 2016-09-08
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Terminated
NCT00983346 2016-07-11
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
University of Utah
Phase 2 Terminated
NCT00522392 2015-06-26
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01062230 2015-04-06
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
University of Arkansas
Phase 2 Terminated
NCT02353468 2015-03-09
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
University of Colorado, Denver
Phase 2 Terminated
NCT02353572 2015-03-09
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
University of Colorado, Denver
Phase 1/2 Terminated
NCT00891033 2015-02-23
Panobinostat/Velcade in Multiple Myeloma
University of Arkansas
Phase 1 Terminated
NCT01537861 2015-01-26
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Terminated
NCT00719901 2015-01-12
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT01078441 2015-01-12
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 2 Terminated